NewzAstraZeneca has engaged in preliminary discussions regarding a potential merger with Bristol Myers Squibb, a deal estimated at US$400 billion. The talks, which have surfaced following AstraZeneca's recent direct listing on the New York Stock Exchange, represent a significant potential consolidation within the pharmaceutical industry.
In-depth summary · AI, neutralAstraZeneca held talks with Bristol Myers Squibb on US$400 billion megadeal : source
How the coverage differs
Same story, different emphasis — here's what each outlet chose to lead with.
businesstimes.com.sg
Focuses on the scale and existence of the merger talks.
Free Malaysia Today (MY)
Highlights the negative market reaction and investor skepticism.